Loading profile…
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
DBA: N/A
EIN 86-3367209 · Snapshot of IRS recognition, filing currency, financial health, and governance.
Building a population-based familial cohort of individuals who are at high-risk of developing pancreatic cancer. In partnership Arbor Research, Precede over the next 5 years will be forming a Consortium of cancer centers from around the world to develop and maintain a common database on the ArborLink platform, including clinical and family history information, as well as cataloguing and tracking of biological samples and imaging data. The scientific goal of the Consortium includes (1) improving risk modeling for pancreatic cancer, based on the genetic and environmental risk factors, (2) developing a validation cohort for an early detection test for pancreatic cancer, (3) testing the concept that screening in this population will saves lives, (4) performing clinical trials using the early detection test.
Total Revenue
$0
FY2023
Total Expenses
$703K
FY2023
Net Assets
$205K
Program Ratio
—
expenses on programs
Employees
—
Volunteers
—
Board Members
—
Voting
—
Independent
8 answers compiled from IRS Form 990, BMF, Pub 78, and the Auto-Revocation List.